Amorfix vCJD assay achieves 100% sensitivity and 100% specificity on 1,000 fresh samples from UK blood donors



    TSX: AMF

    TORONTO, Oct. 17 /CNW/ - Amorfix Life Sciences, a company focused on
treatments and diagnostics for brain wasting diseases, today announced the
best sensitivity and specificity ever reported using its EP-vCJDTM Blood
Screening Assay to test fresh blood plasma samples from anonymous UK blood
donors. Amorfix completed this testing in the laboratories of the National
Institute for Biological Standards and Control (NIBSC) in the United Kingdom.
    Amorfix tested 1,000 fresh blinded human plasma samples which included
samples that were spiked with vCJD brain prions and normal brain. The EP-
vCJDTM Blood Screening Assay scored 100% sensitivity for all spiked samples
down to a 1 in 100,000 dilution of 10% brain homogenate (1/1,000,000 dilution
of vCJD brain). The specificity for all samples was 99.3% on initial testing
and 100% on repeat reactive testing.
    "A major concern for screening human blood donors for vCJD is finding
false positives and then erroneously notifying blood donors and excluding them
from future donations, "said Dr. George Adams, Chief Executive Officer of
Amorfix. "The UK authorities have put forward a 99.9% specificity as an
acceptable performance for a vCJD test on blood donor samples and these first
results suggest we can meet or exceed this requirement."
    NIBSC has asked us to continue testing samples to verify the results and
to determine if frozen samples can similarly be used, as all vCJD patient
samples are frozen. The current testing was conducted with kits manufactured
over 12 months ago which continue to demonstrate excellent shelf life and
stability.

    About Amorfix

    Amorfix Life Sciences Ltd. (TSX:AMF) is a theranostics company developing
therapeutic products and diagnostic devices targeting brain-wasting diseases
including ALS, Alzheimer's Disease, Parkinson's Disease and variant
Creutzfeldt-Jakob Disease (vCJD). Amorfix's proprietary Epitope
Protection(TM) (EP) technology enables it to specifically identify very low
levels of aggregated misfolded proteins (AMP) in a sample of normal protein.
Aggregated misfolded proteins are a common element of many brain wasting
diseases and the ability to identify AMPs and understand their structure and
mechanism of folding are the first steps to developing new treatments for
these devastating diseases. Amorfix's lead programs are a diagnostic blood
screening test for vCJD and a therapy for ALS.

    This information release may contain certain forward-looking information.
Such information involves known and unknown risks, uncertainties and other
factors that may cause actual results, performance or achievements to be
materially different from those implied by statements herein, and therefore
these statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on the Company's current
beliefs as well as assumptions made by and information currently available to
it as well as other factors. Readers are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the date of this
press release. Due to risks and uncertainties, including the risks and
uncertainties identified by the Company in its public securities filings,
actual events may differ materially from current expectations. The Company
disclaims any intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

    %SEDAR: 00022789E




For further information:

For further information: Dr. George Adams, President & Chief Executive
Officer, Amorfix Life Sciences Ltd., Tel: (416) 847-6959, Fax: (416) 847-6899,
george.adams@amorfix.com; James Parsons, Chief Financial Officer, Amorfix Life
Sciences Ltd., Tel: (416) 847-6929, Fax: (416) 847-6899,
james.parsons@amorfix.com

Organization Profile

Amorfix Life Sciences Ltd.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890